don't let your chest tube block your patient’s … › ...brochure-ml004-f-7.25.20141.pdf ·...

4
FLOW BETTER WITH PLEURAFLOW® ACTIVE CLEARANCE TECHNOLOGY™ DON'T LET YOUR CHEST TUBE BLOCK YOUR PATIENT’S RECOVERY.

Upload: others

Post on 26-Jun-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: DON'T LET YOUR CHEST TUBE BLOCK YOUR PATIENT’S … › ...Brochure-ML004-F-7.25.20141.pdf · Our 20FR PleuraFlow removes nearly triple the amount of blood than a traditional 32FR

FLOW BETTERWITH PLEURAFLOW® ACTIVE CLEARANCE TECHNOLOGY™

DON'T LET YOUR CHEST TUBE BLOCK YOUR PATIENT’S RECOVERY.

Page 2: DON'T LET YOUR CHEST TUBE BLOCK YOUR PATIENT’S … › ...Brochure-ML004-F-7.25.20141.pdf · Our 20FR PleuraFlow removes nearly triple the amount of blood than a traditional 32FR

More than 36% of patients su�er from blocked chest tubes.

Blocked chest tubes can lead to Retained Blood Complications in your patients.

Retained Blood Complications (RBC) causes multiple

mechanical and inflammatory complications that may lead

to additional interventions and readmissions.2,3

A recent prospective study found that of these failures,

86% are intra-thoracic and invisible to bedside caregivers1.

The crucial hours post-surgery, when the patient is still

bleeding, are vitally important. Why risk patient outcomes

on a conventional chest tube to evacuate blood from the

surgical site?

Patient outcomes and healthcare costs are seriously impacted by RBC.

hours days weeks months years

3-6%pericardial tamponade,hemothorax

*References available upon request.

ACUTE

9-12%bloody pleural (9-12%) and pericardial (2%) e�usions

SUB-ACUTE

2-3%constrictive pericarditis, fibrothorax

CHRONIC

COST OF CARE

16-23% combined

Complications Requiring Intervention*

LENGTH OF STAY MORTALITY RATE

Unreimbursable Costs Per Patient with RBC4

$28,814per RBC

5.8 days doubledIncrease 3% to 6%

INCREASE55% 2x2x

BLOCKED TUBES LEAD TO COMPLICATIONS

Page 3: DON'T LET YOUR CHEST TUBE BLOCK YOUR PATIENT’S … › ...Brochure-ML004-F-7.25.20141.pdf · Our 20FR PleuraFlow removes nearly triple the amount of blood than a traditional 32FR

Improve Patient SafetyBy eliminating accumulated blood and

fluid at the surgical site, you reduce risky and unwanted complications.

Plus, you will never again have to break

sterility in order to clear a clogged tube.

Minimize Patient DiscomfortOur 20FR PleuraFlow removes nearly triple

the amount of blood than a traditional

32FR drain5 (525 ml vs. 183 ml) and your

patients will benefit from a smaller and more flexible silicone tube.

Reduce Hospital CostsPrevention of a single Retained Blood

Complication incident may cover the

cost of using PleuraFlow ACT in 100

cardiac surgery patients.4

Clearance Loop enables

proactive clearance of

thrombus obstruction from

the chest tube and provides

real-time patency feedback.

KEEP CHEST TUBES CLEARwith PleuraFlow® Active Clearance Technology™ (ACT)Developed by cardiac surgeons, PleuraFlow ACT is a unique system that

proactively clears chest tubes and prevents the retention of blood in the chest cavity. ACT technology is used to maintain tube patency and

clears the pathway to a successful recovery before and after discharge.

Page 4: DON'T LET YOUR CHEST TUBE BLOCK YOUR PATIENT’S … › ...Brochure-ML004-F-7.25.20141.pdf · Our 20FR PleuraFlow removes nearly triple the amount of blood than a traditional 32FR

EU Authorized Representative:

Emergo EuropeMolenstraat 152513 BH, The HagueThe Netherlands

Manufactured For:

ClearFlow, Inc.1630 S. Sunkist St., Suite E Anaheim, CA, US, 92806

ML004-F

Copyright © 2014 ClearFlow, Inc. All Rights Reserved.

™ Trademarks and ® Registered Trademarks of ClearFlow, Inc. US Patents 7,854,728, 7,951,243, 8,048,233, 8,246,752, 8,388,759, and 8,702,662. International Patents AU 2004235782; CA 2,427,628, CA 2,565,303. Other US and international patents pending.

US FDA 510(k): K093565; Health Canada License Number 82994; ARTG Identifier 218317

1 Karimov, J.H., Gillinov, A.M., Schenck, L., et al. Incidence of chest tube clogging after cardiac surgery: a single-centre prospective observational study. Eur J Cardiothorac Surg. 2013;44(6):1029-1036. doi:10.1093/ejcts/ezt140.

2 Shiose, A., Takaseya, T., Fumoto, H., et al. Improved drainage with active chest tube clearance. Interact CardioVasc Thorac Surg. 2010;10:685-688. doi: 10.1510/icvts.2009.229393.

3 Dixon, B., Santamaria, J.D., Reid, D., et al. The association of blood transfusion with mortality after cardiac surgery: cause or confounding? Transfusion. 2013;53(1):19-27. doi: 10.1111/j.1537-2995.2012.03697.x. 

4 2010 Nationwide Inpatient Sample (NIS), from the DHHS Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP). Data extracted using ICD-9 codes from over 313,000 US adult heart surgery patients. Analysis performed by Fletcher Spaght, Inc.

5 Arakawa, Y., Shiose, A., Takaseya, T. et al. Superior Chest Drainage With an Active Tube Clearance System: Evaluation of a Downsized Chest Tube. Ann Thorac Surg. 2011;91:580-583. doi: 10.1016/j.athoracsur.2010.10.018.

References

ACT NOWImprove Outcomes, Lower Costs

Learn more about the innovative new

technology of PleuraFlow® Active

Clearance Technology™ (ACT).

Contact your local representative:

* PleuraFlow ACT System includes a straight silicone chest tube

and clearance apparatus.

CODE DESCRIPTION

20FR PleuraFlow ACT System*

24FR PleuraFlow ACT System*

28FR PleuraFlow ACT System*

32FR PleuraFlow ACT System*

Ordering Information

PF-20

PF-24

PF-28

PF-32

[email protected]

www.clearflow.com